The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / FDA to Review Abuse Deterrent Oxycodone Capsule & More

FDA to Review Abuse Deterrent Oxycodone Capsule & More

April 11, 2018 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

The U.S. Food and Drug Administration (FDA) has scheduled an advisory committee meeting to consider a New Drug Application for Remoxy ER. Additionally, the agency has approved tildrakizumab-asmn to treat adults with moderate to severe plaque psoriasis.

You Might Also Like
  • FDA to Review Abuse-Deterrent Oxycodone Capsule
  • FDA Update: Committees Recommend Approvals for Abuse-Deterrent Opioid & Brodalumab
  • FDA to Review Immediate-Release Oxycodone; Plus NICE Recommends Secukinumab
Also By This Author
  • FDA Approves Ixekizumab for Treating Active Ankylosing Spondylitis

FDA to Review Abuse Deterrent Oxycodone Capsule
In June, the FDA will discuss the New Drug Application for Remoxy ER at an Advisory Committee meeting. Remoxy ER is a 12-hour, abuse-deterrent, extended-release oxycodone in a capsule formulation.1 The capsule contains a sticky, thick, high-viscosity formulation to deter unapproved drug administration routes, including injection, smoking or snorting.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The Prescription Drug User Fee Act target date for the Remoxy ER New Drug Application is Aug. 7.

FDA Approves Tildrakizumab-asmn for Plaque Psoriasis
Tildrakizumab-asmn (Ilumya) has received FDA approval to treat adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.2 The treatment selectively binds to the p19 subunit of interleukin (IL) 23 and inhibits its interaction with the IL-23 receptor, which inhibits the release of proinflammatory cytokines and chemokines. The treatment is administered as 100 mg subcutaneous injections at Weeks 0 and 4, and every 12 weeks thereafter.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

This approval was supported by data from two Phase 3, multi-center, randomized, double-blind, placebo-controlled trials, reSURFACE 1 and reSURFACE 2. The trials included 926 adults treated with either tildrakizumab-asmn (n=616) or placebo (n=310). The primary efficacy endpoints were achieving a Psoriasis Area Sensitivity Index (PASI75) and a Physician’s Global Assessment score of clear or minimal at Week 12 after receiving two doses. Both studies met the primary efficacy endpoints, demonstrating significant clinical improvement with the active drug compared with placebo.


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE
  1. Pain Therapeutics Inc. News release: Pain Therapeutics announces FDA advisory committee meeting for Remoxy ER. FirstWord Pharma. 2018 March 19.
  2. Sun Pharma. News release: Sun Pharma announces U.S. FDA approval of Ilumya (tildrakizumab-asmn) for the treatment of moderate to severe plaque psoriasis. 2018 March 21.

Filed Under: Analgesics, Drug Updates Tagged With: FDA, Remoxy ER, tildrakizumab-asmn, U.S. Food and Drug Administration (FDA)

You Might Also Like:
  • FDA to Review Abuse-Deterrent Oxycodone Capsule
  • FDA Update: Committees Recommend Approvals for Abuse-Deterrent Opioid & Brodalumab
  • FDA to Review Immediate-Release Oxycodone; Plus NICE Recommends Secukinumab
  • Comment Period Open for FDA Draft Guidance on Osteoporosis Treatments; Plus FDA Rejects Abuse-Deterrent Apadaz

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.